GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Paper] ATTAIN-1 — an oral pill with no food restrictions is a bigger deal than the % suggests — 43 comments in the full submission. View in context.
989
c/trialwatch·submitted 17 days ago by u/customs_seizure_sid

[Paper] ATTAIN-1 — an oral pill with no food restrictions is a bigger deal than the % suggests

Paperbranch of 10 comments

Confession thread, sort of. I went from 12.5mg to 5mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 23 weeks later, at which point I had no way of knowing whether the dose increase did anything or whether it would have broken anyway. So now I have…

Read the full submission and all 43 comments →

This branch

10 comments, started 17 days ago
u/aurel_mwangi57 points·17 days ago

the 20 week readout is different from the 14 week readout

replysharereportpermalink
[removed]27 points·17 days ago

[removed by moderator]

replysharereportpermalink
u/customs_seizure_sidOP0 points·17 days ago

Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.

replysharereportpermalink
u/piotr_bruun0 points·17 days ago

Slight fix: the number was 93.7, not 99.3. Decimal point, but a fairly consequential one.

replysharereportpermalink
u/karl_fischer_kev1 point·16 days ago

Slight fix: the number was 93.7, not 99.3.

Disagree on that part. 96.8% and 96.2% on the same vial is normal.

replysharereportpermalink
u/first_hundred1 point·16 days ago

the relative risk reduction in headlines is not the whole story

replysharereportpermalink
u/customs_seizure_sidOP1 point·16 days ago

Yeah, absolute numbers matter more than the press release.

replysharereportpermalink
u/sten_palacios1 point·17 days ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink
u/nils_tulloch1 point·16 days ago

number-needed-to-treat is the house dialect

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →